Abstract Despite an ever-growing prevalence and increasing economic burden of Alzheimers disease (AD) and Parkinsons disease (PD), recent advances in drug development have only resulted in minimally effective treatment
Constantly losing and gaining weight called weight cycling or yo-yo dieting leads to adverse health outcomes, according to the Endocrine Society
Germany continues to exclude obesity medicines from statutory reimbursement while France has set aside EUR 100 million for tightly defined GLP-1 obesity reimbursement, and Rybelsus became commercially available in Germany from July 15, 2025 for type 2 diabetes under AMNOG-negotiated terms
S., Zhang, Z., Liang, Q., Shi, Y., Hua, J
Whether youre starting your journey or looking for ways to optimize your results, our team of experts is ready to help
E.WalshR